Pfizer, Arvinas and breast cancer

Pfizer-Arvinas' breast cancer treatment shows mixed results in late-stage study
Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of patients in a late-stage trial, sending the Connecticut-based biotech's shares down 36% before the bell.
Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader
The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study assessed vepdegestrant against AstraZeneca’s hormone med Faslodex in 624 patients with ER+/HER2- advanced or metastatic breast cancer who had already tried CDK 4/6 inhibitors and endocrine therapy.
Arvinas gets positive breast cancer data, but finds differentiation a hard sell
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a subgroup of breast cancer patients, but not the overall study population.
Pfizer-Arvinas' breast cancer treatment cuts progression for some patients in study
An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients lived without the disease worsening, but failed to achieve statistically significant results in others in a late-stage study.
Pfizer's new drug data in breast cancer draws muted response
Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million in cash and a $350 million equity investment – with another $1.4 billion in backloaded milestone payments.
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug
Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ stock took a 43% tumble on the news, and analysts are downcast on the drug’s prospects.
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.
Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug
Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming late-stage trial data for vepdegestrant, an experimental breast cancer therapy it co-develops with Pfizer (NYSE:PFE).
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend progression-free survival (PFS) in certain patients in a Phase III trial.
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug.
STAT2d
Diseased protein degrader shows mixed results in breast cancer trial
Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression 40% compared to standard treatment for an ...
Endpoints News2d
Arv­inas, Pfiz­er’s PRO­TAC da­ta fall short of hype in breast can­cer
Arvinas/Pfizer's vepdegestrant shows efficacy in mutated breast cancer patients but not in broader population, failing to ...
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...
STAT2d
Bristol buys out cancer cell therapy partner
Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...